Corona Remedies IPO Description – Incorporated in 2004, Corona Remedies is a rapidly growing India-focused pharmaceutical formulation company engaged in developing, manufacturing, and marketing branded products across women’s healthcare, cardio-diabeto, pain management, urology, and other therapeutic areas. The company ranked as the fastest-growing among the top 30 Indian Pharmaceutical Market (IPM) players in domestic sales between MAT June 2024 and MAT June 2025, with a CAGR of 13.58% versus the IPM’s 7.90%.
The company’s diversified portfolio comprises 71 brands, including 27 “engine brands” contributing 72.34% of domestic sales as of MAT June 2025. Chronic and sub-chronic therapies accounted for 70.10% of domestic sales, growing at a CAGR of 20.48%.
Supported by a field force of 2,671 medical representatives across 22 states, Corona holds the 29th rank in the IPM and 17th in covered markets. With two manufacturing facilities in Gujarat and Himachal Pradesh, robust R&D infrastructure, and strategic acquisitions like Myoril from Sanofi, Corona Remedies continues to strengthen its market presence and product innovation pipeline.
Promoters of Corona Remedies – Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta, and Ankur Kirtikumar Mehta
Table of Contents
Corona Remedies IPO Details
| Corona Remedies IPO Dates | 8 – 10 December 2025 |
| Corona Remedies Issue Price | INR 1,008 – 1,062 per share Employee discount – INR 54 per share |
| Fresh issue | NA |
| Offer For Sale | INR 655.37 crore |
| Total IPO size | INR 655.37 crore |
| Minimum bid (lot size) | 14 shares (INR 14,868) |
| Face Value | INR 10 per share |
| Retail Allocation | 35% |
| Listing On | BSE, NSE |
Corona Remedies Financial Performance
| FY 2023 | FY 2024 | FY 2025 | Q1 FY 2026 | |
| Revenue | 884.05 | 1,014.47 | 1,196.42 | 346.54 |
| Expenses | 756.07 | 859.74 | 956.44 | 276.76 |
| Net income | 84.93 | 90.50 | 149.43 | 46.20 |
| Margin (%) | 9.61 | 8.92 | 12.49 | 13.33 |
Corona Remedies Offer News
- Corona Remedies RHP
- Corona Remedies DRHP
- ASBA IPO Forms
- Live IPO Subscription Status
- IPO Allotment Status
Corona Remedies Valuations & Margins
| FY 2023 | FY 2024 | FY 2025 (Pre-Issue) | FY 2025 (Post Issue) | |
| EPS | 14.57 | 14.80 | 24.43 | 24.43 |
| PE Ratio | – | – | 41.26 – 43.47 | 41.26 – 43.47 |
| FY 2023 | FY 2024 | FY 2025 | |
| RONW (%) | 20.79 | 18.84 | 24.65 |
| NAV | 70.06 | 78.55 | 99.14 |
| ROCE (%) | 28.36 | 31.19 | 41.32 |
| EBITDA (%) | 15.27 | 15.89 | 20.55 |
| Debt/Equity | 0.01 | 0.28 | 0.10 |
Corona Remedies IPO GMP Today (Daily Trend)
| Date | Day-wise IPO GMP | Subject to Sauda |
| 4 December 2025 | 301 | 3,300 |
Corona Remedies IPO Subscription – Live Updates
Coming soon
() Shares allotted to anchor investors are not included in these calculations.
Corona Remedies – Comparison With Listed Peer
| Company | PE ratio | EPS | RONW (%) | NAV | Revenue (Cr.) |
| Corona Remedies | 43.47 | 24.43 | 24.65 | 99.14 | 1,196.42 |
| Abbott India | 41.17 | 665.62 | 33.41 | 1,992.14 | 6,409.15 |
| Alkem Laboratories | 31.39 | 181.11 | 18.07 | 1,002.14 | 12,964.52 |
Corona Remedies IPO Allotment Status
Corona Remedies IPO allotment status will be available on Bigshare Services’ website. Click on this link to get the allotment status.
Corona Remedies IPO Dates & Listing Performance
| IPO Opening Date | 8 December 2025 |
| IPO Closing Date | 10 December 2025 |
| Finalization of Basis of Allotment | 11 December 2025 |
| Initiation of refunds | 12 December 2025 |
| Transfer of shares to demat accounts | 12 December 2025 |
| Corona Remedies IPO Listing Date | 15 December 2025 |
| Opening Price on NSE | Coming soon |
| Closing Price on NSE | Coming soon |
Corona Remedies IPO Reviews – Subscribe or Avoid?
Angel One –
Anand Rathi –
Axis Capital –
Antique Stock Broking –
Arihant Capital –
Ashika Research –
Asit C Mehta –
BP Wealth –
Capital Market –
Canara Bank Securities –
Choice Broking –
Dalal & Broacha –
Elite Wealth –
GCL Broking –
Geojit –
GEPL Capital –
Hem Securities –
ICICIdirect –
Investmentz –
Jainam Broking –
DR Choksey –
LKP Research –
Marwadi Financial –
Motilal Oswal –
Nirmal Bang –
Reliance Securities –
SBI Securities –
Samco Securities –
SMC Global –
Swastika Investmart –
Ventura Securities –
Corona Remedies IPO Lead Manager
JM FINANCIAL LIMITED
7th Floor, Cnergy Appasaheb Marathe Marg
Prabhadevi, Mumbai 400 025
Phone: +91 22663 03030
Email: [email protected]
Website: www.jmfl.com
Corona Remedies Offer Registrar
BIGSHARE SERVICES PRIVATE LIMITED
S6-2, 6th Floor, Pinnacle Business Park,
Next to Ahura Centre, Mahakali
Caves Road, Andheri East, Mumbai – 400 093
Phone: +91 22 6263 8200
Email: [email protected]
Website: www.bigshareonline.com
Corona Remedies Contact Details
CORONA REMEDIES LIMITED
CORONA House, C – Mondeal Business Park,
Near Gurudwara, S. G. Highway,
Thaltej, Ahmedabad 380 059, Gujarat,
Phone: +91 79 4023 3000
Email: [email protected]
Website: www.coronaremedies.com
Corona Remedies IPO FAQs
How many shares in the Corona Remedies IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%.
How to apply in the Corona Remedies Public Offer?
The best way to apply for the Corona Remedies public offer is through Internet banking ASBA (know all about ASBA here). You can also apply online through your stockbroker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.
What is the Corona Remedies IPO GMP today?
Corona Remedies IPO GMP today is INR 301 per share.
What is Corona Remedies Subject to Sauda rate today?
Corona Remedies Subject to Sauda rate today is INR 3,300 per application.